Cadila Healthcare Ltd - 532321 - Related Party Disclosure Under Regulation 23(9)
Related Party Disclosure under Regulation 23(9)18-06-2021
Cadila Healthcare Ltd - 532321 - Related Party Disclosure Under Regulation 23(9)
Related Party Disclosure under Regulation 23(9)CADILA HEALTHCARE LTD. - 532321 - Related Party Disclosure Under Regulation 23(9)
Related Party Disclosure under Regulation 23(9)Zydus Cadila's epilepsy drug Brivaracetam gets USFDA tentative nod
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare saidCADILA HEALTHCARE LTD. - 532321 - Transcript Of The 1St Extra Ordinary General Meeting Of The Financial Year 2021-2022 Held On June 11, 2021
Transcript of the 1st Extra Ordinary General Meeting of the Financial Year 2021-2022 of the members of the Company held on June 11, 2021CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Brivaracetam TabletsCadila Healthcare Ltd - 532321 - Disclosure of Voting results of EGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results of EGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click hereCadila Healthcare Ltd - 532321 - Post EOGM Proceedings For The EOGM Held On June 11, 2021
Post EOGM proceedings for the EOGM held on June 11, 2021Cadila Healthcare Ltd - 532321 - Regulation 44(3) Voting Results EOGM Held On June 11, 2021
Regulation 44(3) voting results EOGM held on June 11, 2021Cadila Healthcare Ltd - 532321 - Consolidated Results On Voting Of EOGM Along With Scrutinizers'' Report Held On June 11, 2021
Consolidated Results on voting of EOGM along with Scrutinizers'' Report held on June 11, 2021Upcoming covid-19 portfolio a shot in the arm for Cadila
Strong growth in the domestic market offset the impact of weak sales in the US in the March quarter